Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)

Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)

354
Spira, AvrumBoston University

No involved investigator sites defined.

1) a multi-gene mRNA biomarker measured in cytologically normal large airway epithelial cells identified using genome-wide gene-expression profiling, 2) proteomic profiles measured in bronchial airway epithelial cells, 3) serum glycan antibody signature, 4) hypermethylated sites found in promoter regions of tumor suppressor genes measured in blood, 5) cytokines and growth factors secreted from the tumor microenvironment measured in peripheral blood, and 6) two distinct circulating miRNA signatures measured in the serum and plasma
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
2

To characterize intra or within subject reproducibility and variability To characterize inter or across subject variability by adenoma phenotype (normal vs. adenoma) To evaluate biomarker expression in relation to long term adenoma recurrence

3.1.1   Aim 1 Establish a cohort (n=200) of current and former smokers with indeterminate pulmonary nodules (7mm-25mm) on whom clinical, radiographic and biospecimen repositories are developed and who are followed prospectively until final diagnosis. 3.1.2   Aim 2 Validate the diagnostic accuracy of existing molecular biomarkers in the airway and blood to detect lung cancer in this clinical cohort.
Airway gene-expression biomarker (BU) Airway protein biomarker (VU): LC-MRM-MS analyses Serum glycan biomarker (NYU): Plasma promoter methylation biomarker (JHU): Serum cytokines biomarker (UCLA): Serum/Plasma miRNA biomarker (OSU): Plasma miRNA biomarker (UMD):

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.